cjc-1295 and ipamorelin combination + CJC-1295 / Ipamorelin Peptide Therapy:

Ipamorelin is a selective pentapeptide GHS-R1a agonist studied for its specificity over cortisol, prolactin, ACTH, and aldosterone pathways

In contrast, clinical trial results using apitolisib, an mTOR/PI3K inhibitor combination, in patients with metastatic renal cell carcinoma showed shorter progression-free survival and a higher incidence of grade 3-4 toxicity (233)

It helps to maintain optimal immune response and may assist in fighting against infections, viruses, and other harmful pathogens

Both results show SnCE1 C256A S/T/C_to_A is still processed, suggesting an autoproteolytic processing mechanism not involving these residues (Supplementary Fig